Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02946125 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil
A Phase 2 study, sponsored by Eyenovia.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02946125: Completed Phase 2 study, sponsored by Eyenovia.
NCT02946125 is a Phase 2 study that has completed, run by Eyenovia. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02946125, a Phase 2 study, has completed, sponsored by Eyenovia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 2 study to investigate the safety, efficacy and pharmacokinetics of EYN-1601 for dilation of the pupil. A single microdose of EYN-1601 will be compared to single doses of commercially available phenylephrine hydrochloride 2.5% and 10% ophthalmic solutions.
Primary Outcome
Mean change in pupil diameter from baseline (prior to study drug administration)
Interventions
- COMBINATION_PRODUCT MDD-administered EYN-1601
- DRUG Phenylephrine 2.5% Eyedrop
- DRUG Phenylephrine 10% Eyedrop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT02946125 record still lists
NCT02946125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which MDD-administered EYN-1601 is the first listed.
NCT02946125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02946125 about?
NCT02946125 is a clinical study titled "Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil". This is a Phase 2 study to investigate the safety, efficacy and pharmacokinetics of EYN-1601 for dilation of the pupil. A single microdose of EYN-1601 will be compared to single doses of commercially available phenylephrine hydrochloride 2.5% and 10% ophthalmic solutions.
What is the current status of trial NCT02946125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02946125?
The interventions under investigation include: MDD-administered EYN-1601 (COMBINATION_PRODUCT), Phenylephrine 2.5% Eyedrop (DRUG), Phenylephrine 10% Eyedrop (DRUG).
Who is sponsoring clinical trial NCT02946125?
This trial is sponsored by Eyenovia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02946125's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia